本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日接到公司控股股东及实际控制人王俊民先生的 通知，获悉王俊民先生所持有本公司的部分股份质押展期，具体事项如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2026-009 海思科医药集团股份有限公司 关于控股股东部分股份质押展期的公告 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： ■ 三、备查文件 中国证券登记结算有限责任公司证券质押及司法冻结明细表。 特此公告。 海思科医药集团股份有限公司董事会 2026年01月14日 一、股东股份质押展期的基本情况 ■ 本次质押股份未负担重大资产重组等业绩补偿义务。 二、股东股份累计质押的情况 ...

重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026年1月13日 (二)股东会召开的地点：浙江省仙居县现代工业集聚区丰溪西路9号公司行政楼会议室现场结合线上方 式 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 表决情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，董事长胡健先生主持，会议以现场投票结合网络投票的方式进行表决，会 议的召集、召开和表决方式符合《公司法》、《上市公司股东会议事规则》及《公司章程》的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事8人，列席8人 2、公司董事会秘书兼财务负责人郭军锋先生列席会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于募集资金投资项目结项、调整投资规模，并将节余募集资金永久补充流动资金的议 案 审议结果：通过 2、律师见证结论意见： 本次股东会的召集、召开程序符合《公 ...

Core Viewpoint - The company has established multiple special accounts for fundraising and has undergone changes in the management and usage of these funds, ensuring compliance with regulatory requirements and optimizing the use of idle funds for cash management and project financing [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Fundraising and Account Management - On June 30, 2020, the company signed a five-party supervision agreement for special fundraising accounts with its subsidiaries and banks, establishing accounts at Guangfa Bank and China Construction Bank [1]. - The company has made several changes to its special fundraising accounts, including the establishment of new accounts and the cancellation of old ones, ensuring that all funds are properly managed and transferred [2][3]. - As of September 30, 2025, the company reported a total of RMB 64,276.06 million in invested fundraising, with RMB 8,000.00 million in idle funds managed for cash management purposes [12][17]. Fund Usage and Project Changes - The company has utilized its fundraising for various projects, with specific changes in project funding allocations to optimize resource use and enhance project efficiency [5][6][18][24][25][26]. - The company has received government subsidies totaling approximately RMB 49.89 million, which have contributed to reducing project costs and improving fundraising efficiency [6]. - The company has made adjustments to its project focus, shifting resources towards HIV-related drug development and other strategic areas, while slowing down projects in the oncology sector due to increased competition and resource constraints [24][26][27][28]. Economic Benefits and Performance - The company has reported significant sales revenues from its new drug projects, with sales of RMB 4,884.38 million, RMB 13,354.27 million, and RMB 18,516.06 million for the years 2023, 2024, and the first nine months of 2025, respectively [32]. - The raw material production and research project has achieved a financial internal rate of return of 27.73% and a payback period of 6.50 years, indicating strong economic viability [34]. - The company has successfully completed several clinical projects, with ongoing research expected to yield further economic benefits in the future [18][32][34].

1月13日多瑞医药大宗交易一览 | 成交量（万 | 成交金额（万 | 成交价格 | 相对当日收盘折溢价 | 买方营业 | 卖方营业 | | --- | --- | --- | --- | --- | --- | | 股） | 元） | （元） | （%） | 部 | 部 | | 12.50 | 696.13 | 55.69 | 0.00 | 机构专用 | 机构专用 | 多瑞医药1月13日大宗交易平台出现一笔成交，成交量12.50万股，成交金额696.13万元，大宗交易成交 价为55.69元。该笔交易的买卖双方均为机构专用席位。 证券时报·数据宝统计显示，多瑞医药今日收盘价为55.69元，下跌0.73%，日换手率为1.55%，成交额为 7020.52万元，全天主力资金净流出124.66万元，近5日该股累计下跌1.19%，近5日资金合计净流出 1951.85万元。 两融数据显示，该股最新融资余额为2.02亿元，近5日减少1187.28万元，降幅为5.54%。 据天眼查APP显示，西藏多瑞医药股份有限公司成立于2016年12月22日，注册资本8000万人民币。（数 据宝） （文章来源：证券时报网） ...

Group 1 - The company, Jiangsu Aidi Pharmaceutical Group Co., Ltd., plans to raise up to 185 million yuan through a simplified procedure to issue A-shares, primarily to acquire a 22.23% stake in its subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., for approximately 130 million yuan, and to supplement working capital with 55 million yuan [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, making it one of the few integrated manufacturers in China holding production approvals for both raw materials and injectable formulations [2] - The acquisition of Nanda Pharmaceutical is expected to enhance the company's control over it, optimize financial performance, and maximize synergies, thereby strengthening its competitive position in the human protein sector [3] Group 2 - The stroke incidence in China is rising, with acute ischemic stroke cases projected to increase from 4.1 million in 2023 to 4.9 million by 2027, highlighting a significant unmet clinical need for effective stroke treatments [3] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035, indicating a strong demand for innovative stroke medications [3] - Aidi Pharmaceutical has maintained rapid growth in the HIV sector for three consecutive years, with the market for anti-HIV drugs in China estimated at 7 billion yuan in 2023, projected to exceed 11 billion yuan by 2027 [4] Group 3 - The company is advancing its core HIV pipeline and aims to establish a comprehensive commercialization system for new HIV drugs, addressing the significant challenge posed by the large population of HIV-infected individuals in China [4] - Aidi Pharmaceutical has made significant progress in its HIV drug pipeline, with new drugs like ACC017 and ADC118 entering clinical trials, and is also developing long-acting pre-exposure prophylaxis drugs [5] - The 55 million yuan raised will be used to support operational funding and accelerate the development of core research projects, ensuring the efficient rollout of a diverse and comprehensive HIV drug commercialization strategy [5]

Group 1 - The core point of the article is that Huate Dain (000915) is set to officially launch its melatonin granule product, Manlejing, for online sales on platforms like Alibaba and JD this week, following prior interest reservations [1] - The product will also gradually enter hospitals across various regions in China for sales [1]

Core Viewpoint - The company reported a decline in profits for the third quarter due to routine maintenance in the chemical medicine workshop, the seasonal downturn in industry consumption, increased production capacity from the launch of the sixth phase project, and promotional discounts offered by the company [2] Group 1 - The main reasons for the profit decline include routine maintenance, seasonal consumption downturn, increased production capacity, and promotional discounts [2] - The company raised the price of gold mycin in domestic and other export markets at the end of November, which may positively impact the fourth quarter's performance [2] - Investors are advised to monitor the company's announcements for specific operational updates [2]

Core Viewpoint - Huate Dain (000915) announced that its melatonin granule product, Manlejing, will be available for online purchase on Alibaba and JD.com with a doctor's prescription starting this week, and it will gradually enter hospitals across the country for sales [1]. Company Summary - Huate Dain's melatonin product, Manlejing, is set to launch on major e-commerce platforms, indicating a strategic move to enhance accessibility for consumers [1]. - The company plans to expand its product availability by introducing it to hospitals nationwide, which could potentially increase its market reach and sales volume [1].

格隆汇1月13日丨艾迪药业(688488.SH)公布2026年度以简易程序向特定对象发行A股股票预案，本次发 行募集资金总额不超过（含）18,500.00万元，符合以简易程序向特定对象发行股票的募集资金总额不超 过人民币三亿元且不超过最近一年末净资产百分之二十的规定；扣除发行费用后的募集资金净额将用于 以下项目：收购南大药业22.2324%股权、补充流动资金。 MACD金叉信号形成，这些股涨势不错！ ...

2026年1月13日，山西仟源医药集团股份有限公司（以下简称"仟源医药"）发布公告称，公司第五届董 事会第三十六次会议审议通过了《关于回购注销2025年限制性股票激励计划部分限制性股票的议案》。 因2名激励对象离职不再具备激励资格，公司拟回购注销其已获授但尚未解除限售的限制性股票合计 5.00万股，回购价格为授予价格5.6元/股并支付银行同期定期存款利息，资金来源为公司自有资金。 回购背景及原因 据公告披露，仟源医药于2025年实施了2025年限制性股票激励计划（以下简称"本次激励计划"）。根据 《激励计划》相关规定，"激励对象离职的，包括主动辞职、合同到期且因个人原因不再续约、因个人 过错被公司解聘等，自离职之日起，激励对象已解除限售的限制性股票不作处理，已获授但尚未解除限 售的限制性股票不得解除限售，由公司按授予价格回购注销，并支付银行同期定期存款利息。" 此次涉及回购注销的2名激励对象因离职已不具备激励对象资格，因此公司依据《激励计划》启动回购 注销程序，拟回购注销其持有的尚未解除限售的限制性股票。 回购具体情况 回购数量 根据《激励计划》及董事会决议，本次回购价格为授予价格5.6元/股，并将按银行同期 ...